Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine, Tokyo, Japan.
J Pediatr Surg. 2021 Jul;56(7):1136-1140. doi: 10.1016/j.jpedsurg.2021.03.041. Epub 2021 Mar 26.
To report the sequelae of and preventive strategies for selected lower urinary tract (LUT) complications, i.e., posterior urethral diverticulum (PUD), intraoperative LUT injuries, postoperative dysuria, and fistula recurrence in male imperforate anus (IA) with rectourethral/rectovesical (RU/RV) fistula after laparoscopy-assisted anorectoplasty (LAARP) or posterior sagittal anorectoplasty (PSARP).
153 boys with IA and RU/RV fistula treated 1986-2019 by LAARP (n = 56) or PSARP (n = 97) at two unrelated institutes were studied retrospectively.
After mean follow-up of 17.0 years (range: 36.5 days-32.0 years), the overall incidences of LUT complications were: LAARP (6/56; 10.7%); PSARP (7/97; 7.2%); p = 0.55, comprising PUD: LAARP (n = 5), PSARP (n = 0); p = 0.006; injuries: LAARP (n = 0), PSARP (n = 5); p = 0.16; dysuria: LAARP (n = 1), PSARP (n = 1); p>0.999; and recurrence: LAARP (n = 0), PSARP (n = 1); p>0.999. Mean onset of PUD was 5.1 years (range: 1.0-15.1 years).
PUD: surgery (n = 2/5), conservative (n = 3/5); injuries: intraoperative repair (n = 5/5); dysuria: conservative (n = 2/2), and recurrence: redo PSARP (n = 1/1).
Strategies devised to improve dissection accuracy resolved the specific technical issues causing LUT complications (remnant RU fistula dissection in LAARP and blind posterior access in PSARP). Currently, the incidence of new cases of PUD and LUT injuries is zero.
Level III.
报告腹腔镜辅助肛门直肠成形术(LAARP)或后路矢状位肛门直肠成形术(PSARP)治疗男性肛门闭锁合并直肠尿道/直肠膀胱(RU/RV)瘘后,发生的一些下尿路(LUT)并发症(如后尿道憩室[PUD]、术中 LUT 损伤、术后排尿困难和瘘复发)的后遗症和预防策略。
回顾性研究了 1986 年至 2019 年间在两个不相关的研究所,采用 LAARP(n=56)或 PSARP(n=97)治疗的 153 例男性肛门闭锁合并 RU/RV 瘘患儿,共 198 例次。
平均随访 17.0 年(范围:36.5 天至 32.0 年)后,LUT 并发症的总体发生率为:LAARP(6/56;10.7%);PSARP(7/97;7.2%);p=0.55,包括 PUD:LAARP(n=5),PSARP(n=0);p=0.006;损伤:LAARP(n=0),PSARP(n=5);p=0.16;排尿困难:LAARP(n=1),PSARP(n=1);p>0.999;复发:LAARP(n=0),PSARP(n=1);p>0.999。PUD 的平均发病时间为 5.1 年(范围:1.0-15.1 年)。
PUD:手术(n=2/5),保守(n=3/5);损伤:术中修复(n=5/5);排尿困难:保守(n=2/2),复发:PSARP 再手术(n=1/1)。
为提高解剖准确性而制定的策略解决了导致 LUT 并发症的特定技术问题(LAARP 中残余的 RU 瘘管解剖和 PSARP 中盲后的入路)。目前,新发 PUD 和 LUT 损伤的病例数为零。
III 级。